Associated Papers
The Correlation Among PD-L1 Expression and the Driver Genes Status in Malignant Pleural Effusion of Lung Adenocarcinoma.
Wang R et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2025
ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma.
Yang F et al.
Frontiers in Pharmacology, 2025
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Kozakov D et al.
Frontiers in Medicine, 2025
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer.
Terada N et al.
Translational Lung Cancer Research, 2024
Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma.
L'Hostis A et al.
Npj Systems Biology and Applications, 2023
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Pan Y et al.
Cancer Cell, 2023
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
Hunihan L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines.
da Silva-Oliveira RJ et al.
International Journal of Molecular Sciences, 2022
The regulation of CD73 in non-small cell lung cancer.
Han Y et al.
European Journal of Cancer (oxford, England : 1990), 2022
Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations.
Wei XW et al.
Jto Clinical and Research Reports, 2022
Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.
Jin Y et al.
Bmc Cancer, 2022
Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples.
Grant J et al.
Journal of Clinical Pathology, 2022
Pretreatment HDL-C and ApoA1 are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with TKI.
Ma J et al.
Thoracic Cancer, 2022
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B et al.
Lung Cancer (amsterdam, Netherlands), 2021
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.
Kato Y et al.
International Journal of Clinical Oncology, 2021
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini L et al.
Pharmacogenomics and Personalized Medicine, 2021
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N et al.
Molecular Cancer Therapeutics, 2020
Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma.
Ito M et al.
Jto Clinical and Research Reports, 2020
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Udagawa H et al.
Molecular Cancer Research : Mcr, 2019
The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.
Szpechcinski A et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.
Takahashi A et al.
Scientific Reports, 2018
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation.
Liao D et al.
Cancer Chemotherapy and Pharmacology, 2018
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C et al.
Molecular Medicine Reports, 2018
Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
Uchibori K et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Detecting EGFR Mutations in Patients with Non-small Cell Lung Cancer.
Hammoudeh ZA et al.
Balkan Journal of Medical Genetics : Bjmg, 2018
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Karachaliou N et al.
Ebiomedicine, 2018
Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Xia J et al.
Oncotarget, 2017
Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer.
Kim TJ et al.
Oncotarget, 2017
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK et al.
Lung Cancer (amsterdam, Netherlands), 2017
Characterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer.
Wei B et al.
Pathology, Research and Practice, 2017
Uncommon EGFR mutations in advanced non-small cell lung cancer.
O'Kane GM et al.
Lung Cancer (amsterdam, Netherlands), 2017
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Okuda Y et al.
Cancer Chemotherapy and Pharmacology, 2017
Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2017
Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancer.
Fang YH et al.
Oncotargets and Therapy, 2017
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Silva-Oliveira RJ et al.
Cellular Oncology (dordrecht, Netherlands), 2016
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.
Xu J et al.
Journal of Cancer Research and Clinical Oncology, 2016
Activation of ERK/IER3/PP2A-B56γ-positive feedback loop in lung adenocarcinoma by allelic deletion of B56γ gene.
Ito T et al.
Oncology Reports, 2016
Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.
Clark DJ et al.
Theranostics, 2016
Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
Zhou J et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N et al.
Scientific Reports, 2015
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M et al.
Lung Cancer (amsterdam, Netherlands), 2015
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart EL et al.
Translational Lung Cancer Research, 2015
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Costa C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Melting curve analysis for mutations of EGFR and KRAS.
Furugaki K et al.
Anticancer Research, 2014
The quest to overcome resistance to EGFR-targeted therapies in cancer.
Chong CR et al.
Nature Medicine, 2013
Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.
Weiss GA et al.
Journal of Gastrointestinal Oncology, 2013
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Yasuda H et al.
The Lancet. Oncology, 2012
mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.
Santarpia M et al.
Journal of Translational Medicine, 2011